Leo Pharma has received scientific approval for Enstilar for treatment of psoriasis vulgaris in the EU.

Psoriasis is a chronic, inflammatory skin disease, which is frequently accompanied by multiple physical and psychological comorbidities, such as metabolic syndrome and psoriatic arthritis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Enstilar is an alcohol-free foam formulation that can now be used for treatment of psoriasis in patients 18 years of age or older in the EU.

Leo Pharma president and CEO Gitte Aabo said: "Enstilar is a first-of-its-kind topical spray foam and we believe it will help people living with psoriasis by providing a new type of treatment option that they are looking for."

"We believe it will help people living with psoriasis by providing a new type of treatment option."

Approval is based on the safety and efficacy profile from the four week, pivotal Phase 3a PSO-FAST study and Phase II MUSE study.

During clinical trials, patients treated with Enstilar showed significant improvements in symptoms within the first week and more than half achieved treatment success after four weeks.

Approval leads the way for Enstilar to secure national marketing authorisations by 30 EU countries. National approvals of Enstilar are expected later this year.

In October last year, Enstilar was approved for use by the US Food and Drug Administration (FDA).

More than 2%-4% of the population of western countries suffer from psoriasis. Of this, 80% are affected by psoriasis vulgaris, the most common type of psoriasis.

Topical treatments can be used as first-line therapies for the majority of patients suffering from psoriasis.